Dr Reddy’s Laboratories (NSE: DRREDDY) reported its second-quarter financial results for the period ended September 30, 2021.
The company had total revenue of ₹57.6 billion with a growth of 18% year on year.
Dr Reddy’s reported a net profit of ₹9.92 billion or ₹59.65 per share compared to ₹7.62 billion or ₹45.83 in the same quarter of the previous year.
The global generics business posted a growth of 19% year on year. The Indian business saw sales jump 25% on-year to ₹11.4 billion.
“I am pleased with the improvement in the financial performance across our businesses. While we continue to strengthen our core businesses of generics and APIs, we are also making investments in our long-term growth drivers and deeper innovation capabilities,” said G.V. Prasad, co-chairman and managing director at Dr Reddy’s.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,